(Q39684793)

14 September 2017

title

Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development (English)

1 reference

14 September 2017

0 references

0 references

1 reference

6

Charles M Rice

1 reference

14 September 2017

David Franco

1

1 reference

14 September 2017

Wenjing Li

2

1 reference

14 September 2017

Fang Qing

3

1 reference

14 September 2017

Cristina T Stoyanov

4

1 reference

14 September 2017

Thomas Moran

5

1 reference

14 September 2017

David D Ho

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

29 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

35

1 reference

14 September 2017

page(s)

5676-5685

1 reference

The spread, treatment, and prevention of HIV-1: evolution of a global pandemic

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

New developments in flavivirus vaccines with special attention to yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Fine Mapping of a cis-Acting Sequence Element in Yellow Fever Virus RNA That Is Required for RNA Replication and Cyclization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Essential role of cyclization sequences in flavivirus RNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Yellow fever 17D as a vaccine vector for microbial CTL epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Current Assessment of Yellow Fever and Yellow Fever Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Development of more efficient and effective DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.06.052

1 reference

14 September 2017

1 reference